Wednesday, December 7, 2011, 5:27 PM
While Pharmasset (VRUS) shareholders stand to reap a windfall from Gilead Sciences’ (GILD) $11B takeover offer, its top execs are also in line for fat paydays. According to SEC filings reviewed by Footnoted, VRUS CEO P. Schaefer Price could pocket $255M once the deal closes, and other top brass also would grow much richer.
Thursday, December 1, 2011, 2:36 PM
Benzinga notes shares of Pharmasset (VRUS -1.4%) are trading a little funky this week considering the strong market rally and its blockbuster sale to Gilead Sciences (GILD -0.4%). Despite a pickup in chatter that the deal is in jeopardy - a check with analysts covering GILD say the merger is still a "go."
Monday, November 21, 2011, 7:17 AM
Gilead Sciences (GILD) announces a deal to purchase Pharmasset (VRUS) for $11B in a deal that is expected to close in Q1 and become accretive to Gilead's earnings starting in 2015. The $137/share offer price agreed upon by the firms marks an 89% premium to the closing price of Pharmasset on Friday.
2 Comments[M&A, Healthcare]
Thursday, September 8, 2011, 1:35 PM
Pharmasset (VRUS +4%) shares are on the move after favorable analyst notes: Piper Jaffray initiates coverage at Overweight, and Brean Murray raises its price target to $105 from $87. On top of that, Briefing.com reports hearing that a firm has issued positive comments regarding the company's potential valuation in an M&A scenario.
Comment![Healthcare, On the Move, M&A]